Treatment of osteoporosis in clinical practice: first experience with the Russian generic drug of zoledronic acid
Objective: to evaluate the effect of the generic drug of zoledronic acid on bone mineral density (BMD) and markers of bone metabolism in patients with osteoporosis (OP), as well as possible long-term adverse reactions (AR) 12 months after drug administration.Patients and methods. The study included...
Saved in:
| Main Authors: | N. V. Toroptsova, A. O. Efremova, T. A. Korotkova, O. V. Dobrovolskaya, N. V. Demin, A. Yu. Feklistov, E. Yu. Samarkina, M. V. Cherkasova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2022-05-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1275 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Generic zoledronic acid for osteoporosis: focus on tolerability and safety
by: N. V. Toroptsova, et al.
Published: (2021-10-01) -
Zoledronic acid in the treatment of osteoporosis: indications for use
by: Nataliya Vladimirovna Toroptsova, et al.
Published: (2011-06-01) -
Results of 2-year open multicenter observational study for efficacy, safety, tolerability and quality of life impact of zoledronic acid in women with postmenopausal osteoporosis in real-world settings in Russian Federation
by: O. M. Lesnyak, et al.
Published: (2021-06-01) -
SYSTEMIC OSTEOPOROSIS AND PSORIATIC ARTHRITIS: CURRENT UNDERSTANDING OF THE PROBLEM
by: O. V. Dobrovolskaya, et al.
Published: (2017-10-01) -
Is there an association between osteoporosis and uric acid?
by: N. V. Toroptsova, et al.
Published: (2024-12-01)